INDIANAPOLIS (AP) — Aaron Nesmith, the Indiana Pacers top defender, left Game 3 against the New York Knicks midway through the third quarter Sunday before returning for part of the fourth.
Whether he'll play Tuesday night in Game 4 is unclear.
Coach Rick Carlisle said he inserted Nesmith because he was cleared to play. But his return didn't prevent the Pacers from frittering away a fourth-quarter lead in a 106-100 loss. Nesmith didn't look the same after the injury, and Carlisle said he would withhold judgment about Game 4 until he receives more information Monday.
Nesmith landed awkwardly when he jumped to throw a pass into the corner that sailed high and wound up in the seats.
After play stopped, Nesmith remained down briefly before his teammates helped him up and then motioned for the trainers help. He struggled to put weight on the leg, needed assistance to leave the court and went straight to the locker room.
He was Indiana's primary defender on All-Star guard Jalen Brunson as the Pacers pulled out to a 70-57 lead.
The Pacers still hold a 2-1 lead in the Eastern Conference finals.
AP NBA: https://apnews.com/hub/NBA
Indiana Pacers forward Aaron Nesmith (23) celebrates after scoring against the New York Knicks during the second half of Game 3 of the Eastern Conference finals of the NBA basketball playoffs Sunday, May 25, 2025, in Indianapolis. (AP Photo/AJ Mast)
Indiana Pacers forward Aaron Nesmith walks toward the team bench during the second half of Game 3 of the Eastern Conference finals of the NBA basketball playoffs against the New York Knicks Sunday, May 25, 2025, in Indianapolis. (AP Photo/Jeff Roberson)
NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/
The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.
“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”
“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”
The deployment of Oracle Argus will enable QPS to:
As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.
###
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.
ABOUT ORACLE ARGUS
Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.
Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.
